A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)

BACKGROUND: Stomatitis is one of the main reasons to discontinue everolimus in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (mBC). To decrease stomatitis and subsequently early treatment discontinuations or dose redu...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, M., Lübbe, K., Decker, T., Thill, M., Bauer, L., Müller, V., Link, T., Furlanetto, J., Reinisch, M., Mundhenke, C., Hoffmann, O., Zahn, M.-O., Müller, L., Denkert, C., van Mackelenbergh, M., Fasching, P.A., Burchardi, N., Nekljudova, V., Loibl, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832733/
https://www.ncbi.nlm.nih.gov/pubmed/36356410
http://dx.doi.org/10.1016/j.esmoop.2022.100601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832733/
https://www.ncbi.nlm.nih.gov/pubmed/36356410
http://dx.doi.org/10.1016/j.esmoop.2022.100601

Ejemplares similares